These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

650 related items for PubMed ID: 8882301

  • 1. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.
    Bannwarth B, Péhourcq F, Schaeverbeke T, Dehais J.
    Clin Pharmacokinet; 1996 Mar; 30(3):194-210. PubMed ID: 8882301
    [Abstract] [Full Text] [Related]

  • 2. [Pharmacokinetics of methotrexate in rheumatoid arthritis: therapeutic implications].
    Bannwarth B, Péhourcq F, Lequen L.
    Therapie; 1997 Mar; 52(2):129-32. PubMed ID: 9231507
    [Abstract] [Full Text] [Related]

  • 3. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H, Mayer PR, Wajdula J, Fatenejad S.
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [Abstract] [Full Text] [Related]

  • 4. Methotrexate in rheumatoid arthritis. An update.
    Bannwarth B, Labat L, Moride Y, Schaeverbeke T.
    Drugs; 1994 Jan; 47(1):25-50. PubMed ID: 7510620
    [Abstract] [Full Text] [Related]

  • 5. Influence of biological variables upon pharmacokinetic parameters of intramuscular methotrexate in rheumatoid arthritis.
    Debord J, Carpentier N, Sabot C, Bertin P, Marquet P, Treves R, Merle L, Lachâtre G.
    Int J Clin Pharmacol Ther; 1998 Apr; 36(4):227-30. PubMed ID: 9587050
    [Abstract] [Full Text] [Related]

  • 6. Use of methotrexate in older patients. A risk-benefit assessment.
    Tett SE, Triggs EJ.
    Drugs Aging; 1996 Dec; 9(6):458-71. PubMed ID: 8972245
    [Abstract] [Full Text] [Related]

  • 7. Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis.
    Furst DE.
    Br J Rheumatol; 1995 Nov; 34 Suppl 2():20-5. PubMed ID: 8535644
    [Abstract] [Full Text] [Related]

  • 8. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis.
    Lafforgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquaviva PC.
    J Rheumatol; 1995 May; 22(5):844-9. PubMed ID: 8587070
    [Abstract] [Full Text] [Related]

  • 9. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis.
    Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M.
    J Rheumatol; 2006 Mar; 33(3):481-5. PubMed ID: 16463431
    [Abstract] [Full Text] [Related]

  • 10. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis.
    Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M.
    J Rheumatol; 2004 Apr; 31(4):645-8. PubMed ID: 15088287
    [Abstract] [Full Text] [Related]

  • 11. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment.
    Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Frampton C, James J, Barclay ML.
    Arthritis Rheum; 2009 Aug; 60(8):2248-56. PubMed ID: 19644853
    [Abstract] [Full Text] [Related]

  • 12. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.
    Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R.
    Clin Ther; 2014 Mar 01; 36(3):427-35. PubMed ID: 24612941
    [Abstract] [Full Text] [Related]

  • 13. Optimising low-dose methotrexate for rheumatoid arthritis-A review.
    Lucas CJ, Dimmitt SB, Martin JH.
    Br J Clin Pharmacol; 2019 Oct 01; 85(10):2228-2234. PubMed ID: 31276602
    [Abstract] [Full Text] [Related]

  • 14. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.
    Zhuang Y, Xu Z, Frederick B, de Vries DE, Ford JA, Keen M, Doyle MK, Petty KJ, Davis HM, Zhou H.
    Clin Ther; 2012 Jan 01; 34(1):77-90. PubMed ID: 22169051
    [Abstract] [Full Text] [Related]

  • 15. Optimal administration and dosage of methotrexate.
    Braun J.
    Clin Exp Rheumatol; 2010 Jan 01; 28(5 Suppl 61):S46-51. PubMed ID: 21044433
    [Abstract] [Full Text] [Related]

  • 16. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis.
    Godfrey C, Sweeney K, Miller K, Hamilton R, Kremer J.
    Br J Clin Pharmacol; 1998 Oct 01; 46(4):369-76. PubMed ID: 9803986
    [Abstract] [Full Text] [Related]

  • 17. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis.
    Dervieux T, Zablocki R, Kremer J.
    Rheumatology (Oxford); 2010 Dec 01; 49(12):2337-45. PubMed ID: 20713496
    [Abstract] [Full Text] [Related]

  • 18. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration.
    Schiff MH, Jaffe JS, Freundlich B.
    Ann Rheum Dis; 2014 Aug 01; 73(8):1549-51. PubMed ID: 24728329
    [Abstract] [Full Text] [Related]

  • 19. Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis.
    Vakily M, Amer F, Kukulka MJ, Andhivarothai N.
    J Clin Pharmacol; 2005 Oct 01; 45(10):1179-86. PubMed ID: 16172183
    [Abstract] [Full Text] [Related]

  • 20. Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration.
    Bianchi G, Caporali R, Todoerti M, Mattana P.
    Adv Ther; 2016 Mar 01; 33(3):369-78. PubMed ID: 26846283
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.